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Abstract
Background: To study the relation between the prescription rates o f selected cardiovascular 
drugs (ACE-inhibitors and Angiotensin receptor blockers, beta-blockers, diuretics, and 
combinations), sociodemographic factors (age, gender and socioeconomic class) and concomitant 
diseases (hypertension, coronary heart disease, cerebrovascular accident, heart valve disease, atrial 
fibrillation, diabetes mellitus and asthma/COPD) among patients w ith heart failure cared fo r in 
general practice.
Methods: Data from the second Dutch National Survey in General Practice, conducted mainly in 
2001. In this study the data o f 96 practices w ith a registered patient population o f 374.000 were 
used.
Data included diagnosis made during one year by general practitioners, derived from the electronic 
medical records, prescriptions fo r medication and sociodemographic characteristics collected via 
a postal questionnary (response 76%)
Results: A  diagnosis o f HF was found w ith 2771 patients (7.1 in 1000). Their mean age was 77.7 
years, 68% was 75 years o r older, 55% o f the patients were women. Overall prescription rates fo r 
RAAS-I, beta-blockers and diuretics were 50%, 32%, 86%, respectively, whereas a combination of 
these three drugs was prescribed in 18%. Variations in prescription rates were mainly related to  
age and concomitant diseases.
Conclusion: Prescription is not influenced by gender, to  a small degree influenced by 
socioeconomic status and to  a large degree by age and concomitant diseases.
Background
General practitioners (GPs) play a central role in the diag­
nosis and management of heart failure (HF). Over half of 
the patients with HF are diagnosed in primary care, and 
one third is solely managed by the GPs [1,2]. In the last 15 
years, new insights have changed the treatment of HF. In
the 1970s and 1980s, physicians considered heart failure 
principally as a hemodynamic disorder; from the late 
eighties onwards they realised that it is a neurohormonal 
disorder [3] as well. The new concept has led to the recom­
mendation in most guidelines [4-6] to treat patients with 
stable HF not only with diuretics, but also with inhibitors
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of the renine-angiotensin-aldosterone system (RAAS-Is) 
[7,8] and beta-blockers [9-11]. Currently, angiotensin­
converting enzym-inhibitors (ACE-Is) are first choice 
among the RAAS- inhibiting drugs, but in case of side 
effects and adverse reactions angiotensin II receptor block­
ers (ARBs) are recommended as second choice [12,13]. In 
1996, the Dutch College of General Practitioners issued 
guidelines for the diagnosis and treatment of HF. These 
guidelines did not include beta-blockers in the recom­
mended medication; however, in the revised version of 
2004 beta-blockers were included. In addition to these 
medicines digoxin [14] is still indicated in selected cases, 
and for patients suffering from HF with NYHA class 3 and
4 spironolactone [15] is recommended.
Recent surveys suggest that ACE-Is and beta-blockers are 
underprescribed in general practice [1-17].
The main aim of this study was to investigate the prescrip­
tion rates of RAAS-Is, beta-blockers, diuretics, spironolac­
tone and digoxin for patients diagnosed with HF in 
general practice by using a nationally representative data­
base; these rates reflect the average prescription patterns in 
Dutch general practice.
We have examined the prescription rates of all patients 
known with HF in relation to sociodemographic (age, 
gender and socioeconomic class) and morbidity charac­
teristics (specific concomitant disorders: hypertension, 
coronary heart disease, cerebrovascular accident, heart 
valve disease, atrial fibrillation, diabetes mellitus and 
asthma/COPD). Identification of subgroups with subop­
timal treatment may guide interventions aimed at 
improving the quality of pharmacological treatment by 
GPs.
Methods
Design
Data were obtained from the second Dutch National Sur­
vey of General Practice (DNSGP-2), which was performed 
by the Netherlands Institute for Health Services Research 
(NIVEL) in 2001 [18]. In this survey, 195 GPs (165 GP full 
time equivalents) in 104 practices participated with a total 
practice population of 394.192 (midtime population), 
comprising a 2.5% sample of the Dutch population. For 
various reasons eight of the participating practices were 
excluded, leaving a midtime population of 374.000 (three 
practices did not deliver any morbidity data due to techni­
cal problems, the data of five practices did not meet the 
required quality criteria). The participating GPs were rep­
resentative for Dutch GPs and practices with respect to 
age, gender and location in deprived areas, however, sin­
gle-handed practices were underrepresented (32% instead 
of 44% nation wide). The patient population is represent­
ative for the Dutch population concerning age, gender,
degree of urbanisation, social class and ethnic minority 
groups, and type of health insurance. In the Netherlands, 
GPs have a gatekeeper position in the health care system. 
All non-institutionalised patients are registered with a GP. 
Medical specialists are only accessible after referral by a 
GP. If a specialist starts treatment, in nearly all cases the 
GP will be responsible for the repeat prescriptions.
M easurem en ts
Data about age, gender and type of health care insurance 
(public/private) were derived from the administration of 
the practices. Sociodemographic data of patients were 
obtained by sending a questionnaire by mail to all listed 
patients to collect data about occupational and educa­
tional status and country of birth.
E th ica l app rova l
The study was carried out according to Dutch legislation 
on privacy. The privacy regulation of the study was 
approved by the Dutch Data Protection Authority. 
According to Dutch legislation, obtaining informed con­
sent is not obligatory for observational studies
The overall response was 76.5%. The non-responders 
showed no selection with respect to age and gender, but 
the non-indigenous population was underrepresented in 
the census: 12,5 percent in the response-group versus 17,5 
in the Dutch population.
To examine socioeconomic gradients the data about occu­
pational and educational level were aggregated in three 
socioeconomic classes: high, medium en low. The occupa­
tional level was used as primary marker for social class. In 
case of unknown occupation the highest educational level 
was used as indicator.
Information about morbidity was derived from the elec­
tronic medical records kept by the GP. Data included 
health problems presented within a consultation during 
twelve consecutive months and diagnoses were coded 
using the International classification of primary care 
(ICPC). Also, all GP's prescriptions were extracted and 
coded according to the Anatomical Chemical Classifica­
tion system (ATC). Patients with HF were defined on the 
basis of at least one contact diagnosis with ICPC code K77 
during the observation year. The selected concomitant 
diseases were based on their respective ICPC codes in the 
same year. Hypertension, coronary heart disease, valve 
diseases and atrial fibrillation are not only important 
coexisting disorders but they also contribute to the devel­
opment of HF and play a key role in its progression and 
response to therapy [19].
Prescription rates were calculated as proportions of 
patients with HF. We used chi-square tests to compare the
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effect of gender, age group, socioeconomic status and 
comorbidity on prescription rates.
Results
P a tie n t characteris tics (tab le  1)
In total 2771 patients (7.4 in 1000) were diagnosed as suf­
fering from of heart failure: 1248 (6.7 in 1000) males and 
1523 (8.1 in 1000) females. The mean age of all patients 
was 77,7 years (SD 10.5) ; for males it was 75.2 (SD 10.6) 
years, for women 79.7 years (SD 10.0); 1897 (68%) of all 
patients were 75 years or older. From the age of 45 
onwards, every decade there was a fourfold increase in the 
prevalence rate of HF.
During the registration period 303 patients died; this 
amounted to 11% of all known patients with HF. The 
mean age of the deceased was 82.1 years.
Prescrip tion ra tes (tab le  2)
Combination regimes
A combination of a diuretic with an RAAS-I and a beta­
blocker (triple treatment) is considered as the basic 
regime for patients with HF. We investigated the various 
combinations of these three drugs. This triple treatment 
was used by 18% of all patients. We found statistically sig­
nificant differences between the age-groups and socio­
economic classes: the below-75 years group and the high­
est socio-economic class were prescribed more frequently 
the triple treatment.
Looking at a combination of two of these three drugs, the 
combination diuretics and RAAS-Is occurred in 28.2%, 
diuretics and beta-blockers in 10.6%, and beta-blockers 
and RAAS-Is in 1.3 percent. The combination diuretics- 
RAAS-I was seen more often in the group of 75 years and 
older, the combination of RAAS-I and beta-blocker more 
often in the group below 75 years. Diuretics as mono­
therapy were prescribed in 29.6% of all patients, RAAS-Is 
in 3.0% and beta-blockers in 1.7%. Here again significant 
differences were seen between the age groups.
Prescription rates for the separate drugs
One or more diuretics were used by 86% of all patients: in 
75% of the HF patients loop diuretics were involved. 
RAAS-Is were prescribed in 1373 patients (50%). During 
the observation year 57 patients (2%) switched from an 
ACE-I to an ARB. Beta-blocking drugs were prescribed to 
32% of the patients, spironolactone to 20%, and digoxin to 
25%. Considering gender, no significant differences in pre­
scription rates were seen for any of the medicines under 
investigation.
In the age group of 75 years and older prescription rates for 
diuretics and digoxin were higher, but lower for beta­
blockers compared to the under 75 group. Socioeconomic 
differences were only found for prescription of beta­
blockers with a higher rate in the highest socioeconomic 
class.
Concomitant disorders
Before studying the prescription rates for concomitants 
disorders, we determined in which proportion the 
selected diseases occurred in our population of patients 
with HF (table 3). Overall, 30% of the patients had no 
comorbidity at all, 36 percent one, 23 percent two, 9 per­
cent three and 2 percent had four or more comorbidities. 
Hypertension was the most common comorbidity (31%) 
followed by coronary heart disease (28%), diabetes melli­
tus (20%), asthma/COPD (20%), atrial fibrillation (14%) 
and CVa/t IA (8%)
Comorbidity influenced the prescription rates of the med­
icines under consideration. Patients with coronary heart 
disease, hypertension and diabetes mellitus were taking in 
a higher proportion nearly all drugs under study including 
the triple treatment. As expected, patients with atrial fibril­
lation used more frequently digoxin and patients with 
asthma or COPD less often beta-blockers. The more 
comorbidities, the more medicines were used (data not 
shown). RAAS-Is were used by 70% of the patients with 
three or more comorbidities.
T a b le  1: N u m b e r  o f  p a tie n ts  w ith  H F  and p re va le n ce  ra te  o f  H F  by age and sex
A g e
all
N u m b e r  o f  p a t ie n ts  w i th  H F
male female all
P re v a le n c e  ra te  H F  (/1 000 )
male female
• 0-24 5 1 4 <0.1 <0.1 <0.1
• 25-44 19 1 1 8 0.2 0.2 0.2
• 45-54 71 39 32 1.3 1.4 1.2
• 55-64 224 159 65 5.2 7.5 3.1
• 65-74 555 309 246 21.7 26.3 17.7
• 75 and older 1897 729 1168 91.7 96.7 85.6
• All ages 2771 1248 1523 7.4 6.7 8.1
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M e d ic a tio n A l l S ex B e lo w  o r  a b o ve  75 y SES
Male Female <75 y >=75 y low high
N = 2771 1248 1523 873 I898 I235 253
Trip le treatm ent (% )
• Diuretic and 18.0 18.4 17.7 23.7 15.4 16.7 22.1
RAAS-I and
beta-blocker
Two Drugs (% )
• Diuretic and 28.2 29.0 27.6 21.7 31.2 30.5 26.1
RAAS-I
• Diuretic and 10.6 9.8 1 1.2 I I . I 10.3 10.5 10.7
beta-blocker
• RAAS-I and 1.3 1.1 1.4 1.9 1.0 1.3 2.4
beta-blocker
M onotherapy (°%)
• Diuretic 29.6 28.0 30.9 24.7 31.2 29.1 25.3
monotherapy
• RAAS-I 3.0 3.5 2.5 4.6 2.2 2.8 3.6
monotherapy
• beta-blocker 1.7 2.1 1.7 2.3 1.4 1.7 3.1
monotherapy
Prescription of every drug separately (% )
• Diuretics 86 85 88 83 88 87 83
• RAAS-Is 50 51 48 51 49 50 53
• Betablockers 32 32 32 40 29 31 39
• 20 20 20 20 20 2I 2I
Spironolactone
• digoxin 25 23 26 19 27 25 23
*  bold figures represent statistically significant differences on the chi-square test w ith p < 0.05
Discussion gender. About the percentage of patients with preserved
This study is unique as it describes the prescription pat- left ventricular function we have no information.
terns for HF in an unselected general practice population
in the Netherlands. In comparison with HF patients in The prevalence of 7.4 in 1000 is in line with the findings
clinical trials and in community-based studies, such a of Murphy [24] in Scotland. In most studies only the pre-
population tend to have a higher mean age [20], a higher scription rates of separate drugs were explored, in this
proportion of women [21], and a greater percentage of HF study we investigated also the combined prescription of
with preserved left ventricular function [22,23] With a diuretics, RAAS-Is and beta-blockers. This triad was pre-
mean age of 77.7 years and a female proportion of 55%, scribed to approximately one out of five patients, with a
our study population confirmed the findings for age and significantly higher percentage in the under 75, the higher
T a b le  3: P re s c r ip tio n  ra te s  in p a tie n ts  w ith  H F  in re la t io n  to  c o m o rb id ity *
all CHD HT CVA/TIA AF DM Astma/COPD
N = 2771 N = 769 N = 720 N = 2 I2 N = 387 N = 551 N = 559
M e d ic a tio n  (%)
Triple 18 30 27 I4 23 24 13
Diuretics 87 90 90 89 90 90 92
RAAS-Is 50 60 62 47 55 62 48
Beta-blockers 32 51 45 30 40 35 24
Spironolactone 20 23 21 I3 2I 24 22
digoxin 25 21 24 24 64 29 26
*  bold figures represent statistically significant differences on the chi-square test w ith p < 0.05 
CHD = coronary heart disease HT = hypertension AF = atrrial fibrillation DM = diabetes mellitus
Page 4 of 7
(page number not for citation purposes)
BMC Family Practice 2006, 7:40 http://www.biomedeentral.eom/1471 -2296/7/40
socioeconomic group and in patients with cardiovascular 
comorbidity, and with no differences for gender.
Considering each group of drugs separately: RAAS-Is were 
prescribed in about half of the cases with no significant 
differences for gender, age and socioeconomic status. A 
patient suffering from coronary heart disease, hyperten­
sion or diabetes mellitus had a chance of more than 60% 
to receive a RAAS-I. This proportion increased to 70% in 
case of three or more comorbidities in the same patient. 
beta-blockers were prescribed to one third of all patients 
with a higher proportion in the younger age-group and 
highest socioeconomic class. Persons with coronary heart 
disease had a prescription rate above 50 percent, patients 
with hypertension and atrial fibrillation had prescription 
rates above 40 percent, people suffering from asthma or 
COPD had a lower rate (24%).
Our results demonstrated that age and comorbidity influ­
enced prescriptions substantially, socioeconomic class 
only with regard to the triple treatment, and that gender 
had no influence. In table 4 we summarize the prescrip­
tion rates in other primary care studies and compare them 
with our findings. The prescription behaviour of Dutch 
GPs is approximately as high as in other studies; however, 
beta-blockers and spironolactone seem to be prescribed 
more often in the Netherlands than in the UK. In other 
studies, combination treatments of medicines were not 
investigated.
L im ita tio n s  o f  th is  study
As any study of this type, this study too has its limitations. 
Firstly, we take the GPs' diagnosis of HF at face value, we 
have no independent confirmation of the diagnosis. In 
some studies, doubt has been raised about the validity of 
the diagnosis heart failure made by a GP [28,29]. How­
ever, our study aimed to study the prescription behaviour 
of GPs towards HF patients in primary care, so it seems 
justified to take the GPs' diagnosis as point of departure.
Secondly, no data about the dosages of the medicines 
involved are used. Thirdly, we have no information on the
T a b le  4 : P re s c r ip tio n  ra te s  in  seve ra l s tud ies
severity of the disease in our patient group. Fourthly, we 
can not differentiate between patients suffering from HF 
with left ventricular dysfunction and those with preserved 
left ventricular function.
How to judge our results? Is it acceptable that half of the 
patients receive RAAS-Is, one in three patient a beta­
blocker and one in the five patients triple treatment?
In the IMPROVEMENT of Heart Failure Programme [1] 
the primary care physician's knowledge and perceptions 
about the management of HF were assessed. The conclu­
sion was that knowledge of ACE-Is was high, but the phy­
sicians were less convinced about the benefits of beta­
blockers. Guidelines for HF are largely based on surveys in 
which elderly patients and patients with multiple comor­
bidities are excluded. Moreover, in most studies only 
patients with HF and left ventricular dysfunction are 
included, whereas patients with preserved left ventricular 
function are left out. Scientific evidence about the benefi­
cial effects of RAAS-Is and beta-blockers in patients with 
preserved left ventricular function is scarce [27]. In 2001, 
the guidelines of the Dutch Association of General practi­
tioners did not yet recommend beta-blockers for HF.
An impression of the achievable prescription rates can be 
derived from Brotons [30] and Baxter [31]. Brotons et al. 
determined in a population of persons two years after 
their first myocardial infarction that the achievable stand­
ard for ACE-Is was 50%, whereas 32% were actually 
receiving it ; for beta-blockers these figures were 70% and 
50%, respectively.
Baxter et al. determined in the setting of a geriatric outpa­
tient department the tolerability and symptoms changes 
associated with the introduction of bisoprolol treatment 
in older patients with HF. The bisoprolol was tolerated by 
69% of the 51 patients with a mean age of 78 years. When 
we apply these figures cautiously to our study population 
of patients with heart failure and hypothesize that 30% of 
our population had justified reasons not to use a RAAS-I, 
the achievable prescription rate is 70%; with the actual
This study Pont25 Murphy[24] Key Health Statistics[26] Rutten[27]
Country NL NL Scotland UK NL
No. of patients 2771 2493 I007 17817 103
M ed ication  (% )
• ACE-I 45 42 39 48 40
• ARB 6 9 5 6
• Beta-blocker 32 26 2I II 9
• Spironolactone 20 II 9 II
• digoxin 25 25 22 28
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prescription rate of 50% there is a gap of 20%. Only per­
sons with three or more comorbidities in our population 
received RAAS-Is in a proportion of 70%.
For beta-blockers we can follow a similar reasoning. 
Assuming that 80 percent of the patients is eligible for 
treatment with a beta-blocker and that 30% of the 
patients have justified reasons for not using it, the achiev­
able prescription rate should be 50%. Compared with the 
actual rate of 32%, there is a gap of nearly 20%.
Conclusion
Considering the observed prescription rates, the conclu­
sion must be that, on the one hand, there is room for 
improvement in the treatment of patients with HF in gen­
eral practice, but, on the other hand, the gap between 
achievable standards and actual treatment may be smaller 
than generally suggested. The influence of gender and 
socioeconomic class on prescription rates is not very 
marked, the influence of age and comorbidity is consider­
able.
Despite best practice, it may not be achievable for some 
patients to reach the recommended medication for vari­
ous reasons, such as comorbidity, contraindications or 
side effects. All these reasons will occur more often in an 
elderly population. In the United States, 20 percent of the 
Medicare beneficiaries have five or more chronic condi­
tions and 50 percent are receiving five or more medica­
tions [32]. Viewing disease-specific medication guidelines 
from this perspective, the question raises whether what is 
good for the disease is always best for the patient.
In the Netherlands, the GP has an overview of the whole 
medical history of a patient. Therefore, he is in the best 
position to translate disease guidelines into prescribing 
decisions for individual patients with multiple chronic 
conditions by weighting benefit and harm associated with 
multi-drug regimes. Therefore he should be supported by 
evidence and guidelines which are less disease-driven and 
more patient-driven.
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